InvestSMART

Chimeric Therapeutics Limited (ASX:CHM)

ALERT: Price-sensitive ASX Announcement for CHM
Current share price for CHM : $0.052 0.049 (1,633.33%)+
Announcement
Release
31 Oct 2025 4:58PM
Price at Release
$0.003
Full Release
download
Summary
Chimeric Therapeutics Limited reported their quarterly cash flow for the period ending 30 September 2025. The company had $2.40 million in cash and cash equivalents, down from $5.76 million at the previous quarter's close. The net cash used in operating activities was $5.63 million, primarily due to research and development and staff costs. Financing activities provided a net inflow of $2.27 million, which included proceeds from an equity raise and costs associated with the repayment of a debt facility. The company anticipates reduced cash burn moving forward as it implements cost-cutting measures. Chimeric is advancing its cell therapy programs with ongoing clinical trials, specifically the CHM CDH17 CAR T cell therapy and CHM CORE-NK platform, which are showing promising results in early-stage trials.
Key Points
  • Cash and cash equivalents decreased to $2.40 million at quarter end.
  • Net cash used in operating activities was $5.63 million.
  • Research and development and staff costs accounted for 90% of the expenditure.
  • Proceeds from equity raise amounted to $4.38 million.
  • Repayment of debt facility and transaction costs totaled $2.10 million.
  • CHM CDH17 and CHM CORE-NK therapies are under clinical trials.
  • Cost-cutting strategies are in place to reduce future cash burn.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.